CDC Advises on Limited Nirsevimab Supply and RSV Protection

The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.

Related Keywords

United States , Alaska , American , Marina Demidiuk , Sanofi Beyfortus , Children Program , Centers For Disease , Pfizer , Astrazeneca , Health Alert Network Advisory , Contemporary Pediatrics , Disease Control , Vaccines For Children Program , American Indian , Alaska Native , Nirsevimab , Nirsevimab Supply , Rsv , Rsv Protection Options , Cdc , Cdc Recommendations , Rsvpref Maternal Vaccine ,